Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined disease entity characterized by aggressive clinical behavior, diagnostic complexity, and poor prognosis. Given its rarity and heterogeneous histological presentation, establishing a definitive diagnosis can be challenging and relies heavily on comprehensive molecular and immunohistochemical evaluation. Here, illustrating the challenges highlighted by a real-world case, we describe the diagnostic pathway leading to SMARCA4-UT identification and discuss the differential diagnosis of thoracic tumors, relevant molecular evaluations, the molecular basis of SMARCA4-UT, and treatment implications. Recognition of this recently described entity is crucial, as an accurate diagnosis-as demonstrated by our case-can guide effective therapy and facilitate enrollment in targeted clinical trials.

Authors

Institutions

Publication Details

Journal
The Oncologist
Published
2025-05-01
DOI
https://doi.org/10.1093/oncolo/oyaf121
Citations
2
Primary Topic
Chromatin Remodeling and Cancer
Type
article
Field-Weighted Citation Impact
1.61

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches

Benjamin Herzberg, Junmin Song, Balázs Halmos, A. Gersten
2 citations
The Oncologist
Chromatin Remodeling and Cancer
1.61
article

Thoracic SMARCA4-deficient undifferentiated tumor: diagnostic characteristics, molecular insights, and treatment approaches

Benjamin Herzberg, Junmin Song, Balázs Halmos, A. Gersten
article en
2 citations

Abstract

Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a newly defined disease entity characterized by aggressive clinical behavior, diagnostic complexity, and poor prognosis. Given its rarity and heterogeneous histological presentation, establishing a definitive diagnosis can be challenging and relies heavily on comprehensive molecular and immunohistochemical evaluation. Here, illustrating the challenges highlighted by a real-world case, we describe the diagnostic pathway leading to SMARCA4-UT identification and discuss the differential diagnosis of thoracic tumors, relevant molecular evaluations, the molecular basis of SMARCA4-UT, and treatment implications. Recognition of this recently described entity is crucial, as an accurate diagnosis-as demonstrated by our case-can guide effective therapy and facilitate enrollment in targeted clinical trials.

The OncologistVol. 30(5)
Albert Einstein College of Medicine (US), Montefiore Medical Center (US), Jacobi Medical Center (US), Columbia University (US)
Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Merck, AbbVie, Boehringer Ingelheim, Arcus Foundation, BeiGene, Apollomics, Genentech, Daiichi Sankyo Europe
No poverty
Openalex Percentile: Top 17%
Chromatin Remodeling and Cancer
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.